Hologic takes a very tangible, $2.3 billion Q2 hit
May 4, 2009 by MassDevice staff
Bedford women's health products maker takes a massive second-quarter write-down on intangible assets and goodwill for its Cytyc and Third Wave acquisitions.
Hologic Inc. posted a massive second-quarter loss after taking a $2.34 billion write-down of goodwill and intangible assets on its acquisitions of Cytyc and Third Wave Technologies.
THe Bedford-based women's health products maker's stock slipped more than 10 percent in after-hours trading today, to $14 per share, after posting a high of $15.72 during the day.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
- Medical device sales: Wright Medical's pilot program on rep-less sales process worth watching
Navigation
NEWS
Diabetes: Abbott's glucose monitor software glitch gets FDA's highest-risk recall
The FDA slaps its highest-risk classification on Abbott Labs' FreeStyle InsuLinx blood glucose meter...
Weight loss: GI Dynamics' U.S. clinical trial taxes its coffers
Weight-loss devices maker GI Dynamics tells investors today that the company may seek new funding as...
Medtronic touts European win for Export Advance aspiration catheter
Medical device giant Medtronic announces CE Mark approval in the European Union and imminent...
Covidien restates Q2 financials ahead of pharma spinout | Wall Street Beat
Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its...
Can the FDA keep its user fee promises amid sequester?
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
